Literature DB >> 33974816

Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions.

Muhammad Awidi1, Samer Al Hadidi2.   

Abstract

Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that a prompt improvement of Black Americans participation is warranted.

Entities:  

Mesh：

Year:  2021        PMID： 33974816      PMCID： PMC8258017          DOI： 10.1200/OP.21.00001

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


  46 in total

Review 1.  Reducing cancer disparities for minorities: a multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy.

Authors:  Deborah Watkins Bruner; Michele Jones; David Buchanan; Jose Russo
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

2.  American society of clinical oncology policy statement: disparities in cancer care.

Authors:  Elizabeth Goss; Ana Maria Lopez; Carol L Brown; Dana S Wollins; Otis W Brawley; Derek Raghavan
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

3.  Implicit stereotyping and medical decisions: unconscious stereotype activation in practitioners' thoughts about African Americans.

Authors:  Gordon B Moskowitz; Jeff Stone; Amanda Childs
Journal:  Am J Public Health       Date:  2012-03-15       Impact factor: 9.308

4.  The role of health literacy on African American and Hispanic/Latino perspectives on cancer clinical trials.

Authors:  Kiameesha R Evans; M Jane Lewis; Shawna V Hudson
Journal:  J Cancer Educ       Date:  2012-06       Impact factor: 2.037

Review 5.  Breast cancer in African-American women.

Authors:  Lisa A Newman
Journal:  Oncologist       Date:  2005-01

6.  Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.

Authors:  Aisha T Langford; Ken Resnicow; Eileen P Dimond; Andrea M Denicoff; Diane St Germain; Worta McCaskill-Stevens; Rebecca A Enos; Angela Carrigan; Kathy Wilkinson; Ronald S Go
Journal:  Cancer       Date:  2013-12-10       Impact factor: 6.860

7.  Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000).

Authors:  Kathryn B Arnold; John A Hermos; Karen B Anderson; Lori Minasian; Catherine M Tangen; Jeffrey F Probstfield; Elise D Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-21       Impact factor: 4.254

8.  Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials.

Authors:  Neal J Meropol; Yu-Ning Wong; Terrance Albrecht; Sharon Manne; Suzanne M Miller; Anne Lederman Flamm; Al Bowen Benson; Joanne Buzaglo; Michael Collins; Brian Egleston; Linda Fleisher; Michael Katz; Tyler G Kinzy; Tasnuva M Liu; Seunghee Margevicius; Dawn M Miller; David Poole; Nancy Roach; Eric Ross; Mark D Schluchter
Journal:  J Clin Oncol       Date:  2015-12-23       Impact factor: 44.544

9.  Serum testosterone levels in healthy young black and white men.

Authors:  R Ross; L Bernstein; H Judd; R Hanisch; M Pike; B Henderson
Journal:  J Natl Cancer Inst       Date:  1986-01       Impact factor: 13.506

10.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Authors:  Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544
View more
  4 in total

1.  How inclusive are cell lines in preclinical engineered cancer models?

Authors:  Shreya Raghavan
Journal:  Dis Model Mech       Date:  2022-06-01       Impact factor: 5.732

2.  Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.

Authors:  Samer Al Hadidi; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; Frits van Rhee
Journal:  JAMA Netw Open       Date:  2022-04-01

3.  Disparities in awareness of and willingness to participate in cancer clinical trials between African American and White cancer survivors.

Authors:  Gaurav Kumar; Jungyoon Kim; Paraskevi A Farazi; Hongmei Wang; Dejun Su
Journal:  BMC Cancer       Date:  2022-09-15       Impact factor: 4.638

4.  Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.

Authors:  Raghad Alqazaqi; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; John Shaughnessy; Fenghuang Zhan; Guido Tricot; Frits van Rhee; Samer Al Hadidi
Journal:  JAMA Netw Open       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.